Atea Pharmaceuticals, Inc. (AVIR) vs NeoGenomics, Inc. (NEO)
A side-by-side comparison of Atea Pharmaceuticals, Inc. and NeoGenomics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVIR
Atea Pharmaceuticals, Inc.
$5.17HealthcareDelayed quote: Oct 6, 2026, 12:40 PM EDT
NEO
NeoGenomics, Inc.
$16.80HealthcareDelayed quote: Oct 6, 2026, 12:40 PM EDT
Total return — AVIR vs NEO
growth of $100 · dividends reinvested · last 6yAVIR -83.1% (-25.6%/yr)NEO -53.4% (-11.9%/yr)NEO compounded faster over this window
AVIR NEO
AVIR vs NEO: by the numbers
- •NEO is the larger company ($432M vs $414M market cap).
- •Both run net losses; AVIR's is the smaller (0.00% vs -6.77% net margin).
Metrics side by side
Valuation
| Metric | AVIR | NEO |
|---|---|---|
| Forward P/E | N/A | 91.94 |
| P/S ratio | N/A | 0.56 |
| P/B ratio | 2.03 | 0.55 |
Profitability
| Metric | AVIR | NEO |
|---|---|---|
| Gross margin | 0.00% | 42.92% |
| Operating margin | 0.00% | -8.63% |
| Net margin | 0.00% | -6.77% |
| ROE | -80.96% | -6.60% |
| ROIC | -89.93% | -5.29% |
Growth (annualized)
| Metric | AVIR | NEO |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 9.41% |
| Total return CAGR (5Y) | -34.44% | -15.14% |
Frequently asked
- How have AVIR and NEO total returns compared?
- Over the past 5 years, AVIR delivered -34.44% and NEO delivered -15.14% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.